UniXell Biotechnology Co., Ltd. is a Shanghai-based cell therapy company developing allogeneic induced pluripotent stem cell (iPSC)-derived therapies for neurological disorders. Its lead program UX-DA003, an allogeneic iPSC-derived midbrain dopaminergic progenitor cell therapy, secured FDA IND clearance in June 2026 paired with a parallel NMPA clearance — the first Chinese iPSC Parkinson's program to clear both agencies.
Company Info
Upcoming Milestones & Key Dates
Initiation of parallel Phase 1 clinical trials in U.S. and China for UX-DA003
Clinical Development Pipeline
Recent News
UniXell Biotechnology Secures FDA IND Clearance for UX-DA003, Achieving China-U.S. Dual Breakthrough in iPSC Parkinson's Therapy. (PR Newswire FDA.)
Leadership Team
Chief Executive Officer
Careers & Job Openings